Patient-Reported Outcomes in Head and Neck Cancer (DAHANCA PRO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03918382|
Recruitment Status : Not yet recruiting
First Posted : April 17, 2019
Last Update Posted : April 17, 2019
Weekly electronic reporting of patient-reported outcomes will be tested in a national trial in participants undergoing radiotherapy for head and neck cancer.
The study is a national study under the Danish Head and Neck Cancer Group (DAHANCA) and all 6 centers in Denmark will participate.
The clinical endpoints will be:
- Quality of life
- Objective toxicity score (DAHANCA)
- Opioid treatment
- Tube feeding
- Weight loss
- Compliance to treatment
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Cancer Radiotherapy Side Effect||Other: Electronic Patient-Reported Outcome||Not Applicable|
There is a high level of evidence for improved disease control in head and neck cancer (HNC) using regimens with accelerated radiotherapy and concomitant chemotherapy. These intense regimens can result in severe acute and late side effect. The standard approach for documenting symptomatic adverse events (AEs) in cancer clinical trials involves investigator reporting using the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE). In Denmark, the Danish Head and Neck Cancer Group (DAHANCA) toxicity score has been used as an instrument in assessing objective treatment induced toxicity. New research in other cancer treatments indicate, that systematic patient assessment of side effects may improve treatment outcome. Patient Reported Outcomes (PROs) can be used for symptom monitoring. Interactive use of PRO may secure early recognition of specific symptoms in the individual patient and timely management of side effects.
This trial it is a prospective nationwide, single armed sequential cohort study will investigate the effects of active use of PROs in clinical counselling and decision making during primary or post-operative curative radiotherapy for squamous-cell carcinoma of the head and neck (HNSCC). It will investigate quality of life and the management of side effects in standard clinical counselling (control group) versus standard clinical counselling plus the PRO (PRO group). The EORTC QLQ-C30 (quality of life questionnaire) and EQ-D5-L5 will be answered in both groups. In the PRO group the participants will be asked to complete the electronic PRO (PRO CTCAE™ HNC relevant items supplemented by HNC specific items fra the EORTC library) weekly. The electronic PRO questionnaire is designed to give feedback to treating physician and nurses at visits during and shortly after radiotherapy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||291 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||
A prospective nation-wide, sequential cohort study.
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Management of Side Effects in Head and Neck Cancer by Systematic Use of PRO During Radiotherapy- The National DAHANCA PRO Study|
|Estimated Study Start Date :||May 1, 2019|
|Estimated Primary Completion Date :||May 1, 2021|
|Estimated Study Completion Date :||May 1, 2022|
No Intervention: Control group
First phase. 97 participants. This group will continue standard procedure regarding side effect registration and handling. When the 97 patients have been included and have finished their radiotherapy the second phase will be initiated.
Experimental: PRO group
Second phase. 194 participants. This group will be assigned to the intervention which is weekly electronic Patient-Reported Outcomes. Patients report the symptoms (PRO) on a tablet before each weekly control visit. The clinician will use the patients PRO answers as part of the consultation. The PRO symptoms consist of head and neck relevant items fra PRO-CTCAE™ (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) and EORTC (European Organisation for Research and Treatment of Cancer) item library.
Other: Electronic Patient-Reported Outcome
Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
- Quality of life measured by EORTC QLQ C30 [ Time Frame: With in the first 2 months ]Registration of differences in quality of life between the two groups in the study. EORTC QLQ-C30(scale range 0-100, a higher score indicating better quality of life) will be used for as quality of life measurement. The scores will be presented graphically in separate figures. Differences between the groups will be tested using t-test and analysis of covariance.
- Quality of life (QOL) measured by EuroQol EQ-5D-5L. [ Time Frame: With in the first 2 months ]EQ-5D-5L measures individual generic health status using 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each dimension has 5 levels depending on severity of symptoms (1 no problems, 5 extreme problems) and a VAS (visual analogue scale). The scores can then be converted into a single index number. The index value will be used for calculation of quality-adjusted life years (QALYs) for a health economic analysis of the intervention. The scores will be presented graphically in separate figures. Differences between the groups will be tested using t-test and analysis of covariance.
- DAHANCA toxicity score [ Time Frame: Within the first 4 months ]DAHANCA toxicity score is an objective grading of the patients symptoms by the clinician. Scale 0-4, where 0 is no/nothing and 4 is severe. Registration of differences in DAHANCA toxicity score and electronic PRO
- Weight loss [ Time Frame: Within the first 4 months ]Registration of differences in weight loss in the two groups.
- Hospitalization due to toxicity expect tube-feeding and patients reported experience [ Time Frame: Within the first 4 months ]Number of hospitalizations reported in the medical record at the control visit 2 months after end af radiotherapy
- Compliance to cisplatinum [ Time Frame: Within the first 2 months ]Number of participants completing planned Cisplatinum
- Time to opioid treatment [ Time Frame: Within the first 3 months ]Registration of differences in time to opioid treatment in the two groups
- Time to tube-feeding/other feeding [ Time Frame: Within the first 3 months ]Registration of differences in time to Time to tube-feeding/other feeding in the two groups
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03918382
|Contact: Cecilie Holländer-Mieritz, MD||+45 email@example.com|
|Contact: Helle Pappot, MD, DMSc||+45 firstname.lastname@example.org|
|Aalborg University Hospital||Not yet recruiting|
|Contact: Maria Andersen, MD|
|Herlev Hospital||Not yet recruiting|
|Contact: Elo Andersen, MD|
|Rigshoapitalet||Not yet recruiting|
|Contact: Claus A. Kristensen, MD, PhD|
|Zealand Hospital||Not yet recruiting|
|Contact: Mohammad Farhadi, MD|
|Odense University Hospital||Not yet recruiting|
|Contact: Jørgen Johansen, MD, PhD|
|Aarhus University Hospital||Not yet recruiting|
|Contact: Hanne Primdahl|
|Principal Investigator:||Cecilie Holländer-Mieirtz, MD||Rigshospitalet, Denmark|